Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study (Q45204128)
scientific article published in December 2004
Language:
(P31) (Q13442814)
(P304) 2445-2449
(P407) (Q1860)
(P433) 12
(P478) 45
(P577) Wednesday, December 1, 2004
(P1433) (Q6534493)
(P1476) "Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study" (language: en)
(P2093) Rudolf Weide
Annette Pandorf
Jochen Heymanns
Hubert Köppler
(P2860) (Q43985638)
(Q33773306)
(Q41262857)
(Q34662857)
(Q40634072)
other details
description scientific article published in December 2004

External Links